Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Carbohydrate Placebo Clear all
Completed Not applicable Interventional

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

NCT00002071
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 29, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

NCT02668653
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia
Interventions
Chemotherapy, Quizartinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
11
States / cities
Gainesville, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 29, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

NCT02157506
View directory record Official record
Conditions
Heart Failure, Decompensated Heart Failure, Acute Heart Failure
Interventions
CXL-1427, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Gainesville, Florida • Jacksonville, Florida • Macon, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 29, 2026, 1:02 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin

NCT01785615
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 29, 2026, 1:02 PM EDT
Terminated Phase 2 Interventional Results available

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

NCT03152552
View directory record Official record
Conditions
Diabetes Mellitus and Heart Failure
Interventions
LIK066, Placebo, Empagliflozin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
21
States / cities
Huntsville, Alabama • Carmichael, California • Concord, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 29, 2026, 1:02 PM EDT
Terminated Phase 4 Interventional Results available

Steroid Use in Non-RSV Bronchiolitis

NCT04221087
View directory record Official record
Conditions
Bronchiolitis, Viral
Interventions
Placebos, Dexamethasone Oral
Drug
Lead sponsor
Allison Williams
Other
Eligibility
1 Day to 2 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 29, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Analyzing Female Trauma Exposed Responses to a Medication

NCT01814332
View directory record Official record
Conditions
Stress Disorders, Post-traumatic
Interventions
GSK561679, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 29, 2026, 1:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glyburide Healthy Volunteer Study

NCT01716338
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glyburide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 29, 2026, 1:02 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Leucine for Depression Study (L-DEP)

NCT03557684
View directory record Official record
Conditions
Depression
Interventions
leucine, PO placebo, lipopolysaccharide (LPS), IV placebo
Dietary Supplement · Other · Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 29, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Burn Healing and Analgesia With Propranolol

NCT00934947
View directory record Official record
Conditions
Burns, Pain
Interventions
Propranolol, Placebo, Propanolol
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 59 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Chapel Hill, North Carolina • Wake Forest, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 29, 2026, 1:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents

NCT02822937
View directory record Official record
Conditions
Healthy
Interventions
Methylphenidate, Triazolam, Project: EVO, Placebo
Drug · Other
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
40 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 29, 2026, 1:02 PM EDT
Active, not recruiting Phase 2 Interventional

MTT for Children With ASD Who Have Gastrointestinal Disorders

NCT04182633
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions
vancomycin, Miralax, intestinal microbiota, placebo vancomycin, Miralax, placebo intestinal microbiota
Combination Product
Lead sponsor
Arizona State University
Other
Eligibility
5 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Sep 29, 2026, 1:02 PM EDT
Not yet recruiting Phase 2 Interventional

Palmitic Acid and Human Microvascular Function

NCT06683534
View directory record Official record
Conditions
Microvascular Dysfunction, Microvasculature, Cardiovascular Diseases, Cardiovascular Diseases (CVD), Microvascular Health, Obesity and Overweight
Interventions
Quercetin (dietary supplement), Placebo
Dietary Supplement · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 29, 2026, 1:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects

NCT02229214
View directory record Official record
Conditions
Obesity
Interventions
Qsymia, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 29, 2026, 1:02 PM EDT
Completed Phase 3 Interventional

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

NCT01168791
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
doxorubicin in combination with palifosfamide-tris, doxorubicin in combination with placebo
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Sep 29, 2026, 1:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy

NCT01765218
View directory record Official record
Conditions
Hypoxic Ischemic Encephalopathy
Interventions
Topiramate, Placebo
Drug
Lead sponsor
Kristin R Hoffman
Other
Eligibility
Up to 6 Hours
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 29, 2026, 1:02 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Ferritin and Iron Burden in SAH sIRB

NCT03754725
View directory record Official record
Conditions
SAH, Dementia
Interventions
Deferiprone pill, placebo, Montreal Cognitive Assessment
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Iowa City, Iowa • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 29, 2026, 1:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

NCT00831506
View directory record Official record
Conditions
Alzheimer Disease, Huntington Disease
Interventions
digoxin, dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2009 · Synced Sep 29, 2026, 1:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PPARγ Agonist Treatment for Cocaine Dependence

NCT02774343
View directory record Official record
Conditions
Cocaine Use Disorder, Alcohol Use Disorder
Interventions
Pioglitazone, Placebo, Therapy, Contingency Management
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 29, 2026, 1:02 PM EDT
Withdrawn Phase 2 Interventional

4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy

NCT03658408
View directory record Official record
Conditions
Prostate Disease
Interventions
4-aminopyridine, placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
45 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 29, 2026, 1:02 PM EDT
Not listed Phase 4 Interventional

Ovulation Induction With Clomiphene Citrate and Dexamethasone

NCT01856062
View directory record Official record
Conditions
Infertility
Interventions
Placebo, Dexamethasone
Drug
Lead sponsor
San Antonio Military Medical Center
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Sep 29, 2026, 1:02 PM EDT
Completed Phase 4 Interventional Results available

Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach

NCT04112368
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone 200mg, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 29, 2026, 1:02 PM EDT
Terminated Phase 3 Interventional Results available

Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery

NCT03682367
View directory record Official record
Conditions
Cancer of Head and Neck, Narcotic Use
Interventions
Gabapentin, Placebo - Concentrate
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Sep 29, 2026, 1:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Watermelon on Cardiometabolic Health

NCT07006636
View directory record Official record
Conditions
Cardiometabolic Health Indicators, Whole-body Antioxidant Capacity
Interventions
Watermelon Juice + liquid meal test at baseline, Sweetened placebo beverage +liquid meal test at baseline
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 29, 2026, 1:02 PM EDT